Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28514047 | 1.00 | EGFR (0.50) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL20876893 | 0.95 | LTA4H (0.53) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL22362633 | 0.95 | LTA4H (0.53) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL483535 | 0.94 | ALDH1A1 (0.52) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL311817 | 0.94 | EGFR (0.50) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL22546606 | 0.94 | EGFR (0.50) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL483762 | 0.94 | EGFR (0.50) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL20876849 | 0.92 | PPARA (0.55) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL2714607 | 0.92 | PPARA (0.55) | EGFRCTSKBCL2LTA4HPTPN1 | |
| SCHEMBL2727271 | 0.92 | PPARA (0.55) | EGFRCTSKBCL2LTA4HPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356154-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | BIOGEN INC. | 2022-11-10 | — | — | US | disclosed |
| CN-112153968-A | Process for the preparation of alpha-carboxamide pyrrolidine derivatives | 生物基因公司 | 2020-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220356154-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | CPS1, PDF, PCCA | EGFR 3575/4885CTSK 698/4885BCL2 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.